European Commission approves Roche’s Susvimo® for nAMD treatment
Roche says the European Commission approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for neovascular age-related macular degeneration (nAMD).
Story updates
03:51:42 PM UTC
SquawkNews
Roche received European Commission approval for Susvimo (ranibizumab 100 mg/mL) to treat neovascular age-related macular degeneration, enabling continuous delivery via its refillable Contivue implant.Material DetailsContext by AI AnalystThis is a mid-cycle regulatory milestone extending Susvimo’s r…
Basel, 21 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of vision loss in people over the…